Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Jubilant Epicore LLC has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, so the current prosecution record follows one examiner-specific path. Counsel can concentrate on the biotechnology or pharmaceutical issues presented in that action and on the support for the pending claim scope.
JACKSON, SHAWQUIA is the busiest examiner, with 1 pending matter. The examiner accounts for the entire reported docket. A focused response should address the outstanding grounds directly and maintain precise alignment between any amendment and the application’s disclosed biological or pharmaceutical subject matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842771 | DUAL LSD1/HDAC INHIBITORS | JACKSON, SHAWQUIA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842771 | DUAL LSD1/HDAC INHIBITORS | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJubilant Epicore LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Shawquia Jackson has the most, with 1 of Jubilant Epicore LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
